key: cord-0784448-l8llugvl authors: Salvetti, Sara; Lavinia, Federica; Rosi, Nico; Vanni, Simone; Masotti, Luca; Tarquini, Roberto; Guarducci, Silvia; Rossolini, Gian Maria; Montenora, Iolanda title: A rapid and cost-effective diagnostic algorithm for the detection of SARS-CoV-2 infection in the emergency area by combining highly sensitive antigenic test and RT-PCR date: 2022-05-23 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2022.115727 sha: 225e79c63b2be9fcbd9e3331961fa4b65fe7a93a doc_id: 784448 cord_uid: l8llugvl A diagnostic algorithm for SARS-CoV-2 infection in patients admitted to the emergency area, based on a combination of rapid antigen and molecular testing, has been evaluated with 3070 nasopharyngeal swabs. Compared to molecular test alone, the proposed algorithm allowed to significantly reduce costs and average time to results. Highlights  Diagnosis of SARS-CoV-2 infection is crucial to limit virus spread in emergency area  Misidentified diagnosis can expose healthy patients to a risk of nosocomial infection  Development of diagnostic pathways allow savings and reduction of time to results A diagnostic algorithm for SARS-CoV-2 infection in patients admitted to the emergency area, based on a combination of rapid antigen and molecular testing, has been evaluated with 3070 nasopharyngeal swabs. Compared to molecular test alone, the proposed algorithm allowed to significantly reduce costs and average time to results. The COVID-19 pandemic has been a major stressor for the healthcare system worldwide [1, 2] . A prompt and accurate diagnosis is crucial to identify infected individuals and limit the spread of the virus in healthcare settings, particularly with patients admitted to the emergency department (ED). In fact, in this setting a delay in releasing results may negatively reflect on time-dependent interventions and impair the efficient turn-around of patients, while the test accuracy is a matter of major concern since false-positive or -negative results can lead to wrong admission of patients to the COVID-19 or non-COVID-19 settings and expose healthy patients to a risk of nosocomial infection. Viral RNA detection by molecular techniques (e.g., RT-PCR) is the gold standard for the diagnosis of SARS-CoV-2 infection [3, 4] . However, it is expensive and usually has a time to results (TTR) of several hours. Rapid molecular tests, such as the Xpert ® Xpress SARS-CoV-2 (GeneXpert ® , Cepheid, USA) have been released, which may be very useful for COVID-19 diagnosis in the ED setting. Nevertheless, these platforms are very expensive and affected by a low processivity. Recently, a quantitative and fully automated antigen test based on chemiluminescence enzymeimmunoassay has been launched on the market [5] . This assay, named Lumipulse ® G SARS-CoV-2 Ag (LPG) (Fujirebio, Japan) , is an accurate diagnostic tool for SARS-CoV-2 [6, 7, 8, 9] . Nevertheless, using this test, a variable percentage of false-positive results has been reported [10, 11] , and a grey zone (between 1.34 and 10.0 pg/mL) has been suggested by the Manufacturer. The present study was aimed at developing a diagnostic algorithm for the detection of SARS-CoV-2 infection in patients admitted to the ED, to rapidly assign them to COVID or non-COVID settings. were immediately analysed using a molecular-fast (MF) assay (i.e., GeneXpert ® ) as patients were judged to require a time-dependent intervention following triage. The remaining 2659 samples, including 636 from symptomatic and 2023 from asymptomatic patients, were analysed with the LPG antigen test, using the Lumipulse 600II automated system, after centrifugation at 5000 g for 5' [9] , and were also tested with the SARS-CoV-2 ELITe MGB ® RT-PCR assay (ELITechGroup, France). Statistical analyses were carried out using the RT-PCR as the reference test for the diagnosis of SARS-CoV-2 infection (http://vassarstats.net). The antigen test detected 71 specimens with a value of ≥50.0 pg/mL, 211 specimens with a value between 1.0 and <50.0 pg/mL, and 2377 specimens with a value <1.0 pg/mL (these two cut-off values were formally suggested by the Health Authority of the Tuscan regional Government [12] for interpretation of results of the LPG antigen test, according to the results of a large multi-centre regional survey). Confirmation by molecular testing yielded variable results for the different categories (Table 1) (Table 1) . Altogether, these data suggested that: i) LPG is a valid diagnostic assay showing overall high sensitivity and specificity; ii) shifting the cut-off of the antigen test up to 50.0 pg/mL, might avoid the occurrence of false positive results; iii) a grey zone for samples with an antigen concentration between 1.0 and <50.0 pg/mL should be considered, confirming them by RT-PCR; iv) the slight decrease of NPV (95.0% vs 98.0%) observed in symptomatic patients when the cut-off of the antigen test was 50.0 pg/mL, could be by-passed confirming negative swabs from these patients by RT-PCR. In conclusion, since LPG demonstrated good performance compared to RT-PCR, we propose a renewed algorithm for the diagnosis of SARS-CoV-2 infections of patients from the ED (Fig. 1) , which is intended for patients who do not require time-dependent intervention (the latter are always tested with the MF assay). According to this algorithm, the quantitative LPG antigen test is initially Pag. 5 performed, and when the sample shows a result ≥50.0 pg/mL, the patient is managed in a COVID path. When sample shows a result between 1.0 and <50.0 pg/mL (grey zone), the SARS-CoV-2 ELITe MGB ® RT-PCR assay is used as a reflex test and the patient is managed in a COVID or COVID-free paths based on the molecular test result. Finally, when sample shows a result <1.0 pg/mL, the asymptomatic patient is directly managed in a COVID-free path, while the sample from a symptomatic patient is subjected to confirmatory RT-PCR assay. We would like to thank all the technical staff of the Microbiology Unit, San Giuseppe Hospital, for the excellent assistance during the study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All the authors declare the absence of any dual or conflicting interest. The study was approved by the Institutional Review Board of the Emergency Department of the Azienda USL Toscana Centro (n° 05220), and informed consent was obtained from all subjects. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) A novel coronavirus from patients with pneumonia in China World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance SARS-CoV-2 infection and the COVID-19 pandemic emergency: the importance of diagnostic methods Europe announces CE Marking of the fully automated Lumipulse ® G SARS-CoV-2 antigen assay and the rapid antigen device ESPLINE ® SARS-CoV-2 Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs including from seven serially followed patients Prospective study of 1308 nasopharyngeal swabs from 1033 patients using the LUMIPULSE SARS-CoV-2 antigen test: comparison with RT-qPCR Evaluation of Lumipulse ® G SARS-CoV-2 antigen assay automated test for detecting SARS-CoV-2 nucleocapsid protein (NP) in Pag nasopharyngeal swabs for community and population screening Evaluation of three immunoassays for the rapid detection of SARS-CoV-2 antigens Another false-positive problem for a SARS-CoV-2 antigen test in Japan Evaluation of false positives in the SARS-CoV-2 quantitative antigen test Linee di indirizzo per la gestione del prelievo e delle analisi dei test molecolari, dei test antigenici e dei test sierologici nell'ambito delle infezioni da SARS-CoV-2. Sostituzione Allegato A della DGRT 1371/2020 SS; Writing-Review & Editing Supervision: IM, GMR. Legends Pag. 9